HIV Integrase Inhibitors

• 

  Subject Areas on Research

  • Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. 
  • Cobalamin inhibition of HIV-1 integrase and integration of HIV-1 DNA into cellular DNA. 
  • Integramides A and B, two novel non-ribosomal linear peptides containing nine C(alpha)-methyl amino acids produced by fungal fermentations that are inhibitors of HIV-1 integrase. 
  • Integrase inhibitors in late pregnancy and rapid HIV viral load reduction. 
  • Isolation, structure, absolute stereochemistry, and HIV-1 integrase inhibitory activity of integrasone, a novel fungal polyketide. 
  • Isolation, structure, and HIV-1 integrase inhibitory activity of Cytosporic acid, a fungal metabolite produced by a Cytospora sp. 
  • Nef expressed from human immunodeficiency virus type 1 extrachromosomal DNA downregulates CD4 on primary CD4+ T lymphocytes: implications for integrase inhibitors. 
  • Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivo. 
  • Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C). 
  • Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation.